UBS Group AG Acquires 469,547 Shares of Dianthus Therapeutics, Inc. $DNTH

UBS Group AG raised its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 342.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 606,620 shares of the company’s stock after purchasing an additional 469,547 shares during the quarter. UBS Group AG’s holdings in Dianthus Therapeutics were worth $24,999,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. increased its stake in Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $135,000. Palumbo Wealth Management LLC increased its stake in Dianthus Therapeutics by 125.1% during the 4th quarter. Palumbo Wealth Management LLC now owns 14,967 shares of the company’s stock valued at $617,000 after purchasing an additional 8,317 shares in the last quarter. SG Americas Securities LLC bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $765,000. Finally, JPMorgan Chase & Co. increased its stake in Dianthus Therapeutics by 626.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,124 shares of the company’s stock valued at $2,681,000 after purchasing an additional 58,746 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Trading Up 0.1%

DNTH stock opened at $86.84 on Monday. The company’s 50 day moving average is $81.01 and its 200 day moving average is $56.30. The stock has a market cap of $4.75 billion, a price-to-earnings ratio of -21.03 and a beta of 1.18. Dianthus Therapeutics, Inc. has a 1-year low of $16.64 and a 1-year high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.22. The company had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DNTH has been the subject of a number of recent research reports. Oppenheimer boosted their price target on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research note on Monday, March 9th. Wells Fargo & Company began coverage on shares of Dianthus Therapeutics in a research note on Thursday, March 19th. They set an “overweight” rating and a $135.00 price target for the company. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Monday, March 9th. Robert W. Baird upped their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. Finally, Raymond James Financial upgraded shares of Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $63.00 to $123.00 in a research note on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $117.82.

Dianthus Therapeutics News Roundup

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Dianthus Therapeutics and set a $130 price target, suggesting meaningful upside from current levels.
• Positive Sentiment: The firm raised several earnings estimates for Dianthus Therapeutics, including FY2026 EPS to ($4.81) from ($6.21) and FY2027 EPS to ($5.49) from ($6.04), which may be viewed as improved outlook revisions.
• Neutral Sentiment: HC Wainwright also updated quarterly EPS forecasts for Q2 2026, Q3 2026, Q4 2026, and multiple 2027 quarters, but these remain negative EPS estimates as the company is still expected to be unprofitable.

Insider Buying and Selling

In related news, EVP Ryan Savitz sold 8,224 shares of the firm’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total value of $738,844.16. Following the completion of the sale, the executive vice president owned 8,224 shares of the company’s stock, valued at $738,844.16. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marino Garcia sold 122,918 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $10,016,587.82. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 323,021 shares of company stock worth $26,564,008. 3.02% of the stock is owned by company insiders.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.